eQTL analysis in systemic sclerosis identifies new candidate genes associated with multiple aspects of disease pathology

To identify the genetic variants that affect gene expression (expression quantitative trait loci, eQTLs) in systemic sclerosis (SSc) to investigate their role in the pathogenesis of the disease. We performed an eQTL analysis using whole blood sequencing data of 333 SSc patients and 524 controls and...

Full description

Saved in:
Bibliographic Details
Published inArthritis & rheumatology (Hoboken, N.J.)
Main Authors Kerick, Martin, González-Serna, David, Carnero-Montoro, Elena, Teruel, Maria, Acosta-Herrera, Marialbert, Makowska, Zuzanna, Buttgereit, Anne, Babaei, Sepideh, Barturen, Guillermo, López-Isac, Elena, Lesche, Ralf, Beretta, Lorenzo, Alarcon-Riquelme, Marta E, Martin, Javier
Format Journal Article
LanguageEnglish
Published United States 17.01.2021
Online AccessGet full text

Cover

More Information
Summary:To identify the genetic variants that affect gene expression (expression quantitative trait loci, eQTLs) in systemic sclerosis (SSc) to investigate their role in the pathogenesis of the disease. We performed an eQTL analysis using whole blood sequencing data of 333 SSc patients and 524 controls and integrated them with SSc GWAS data. We integrated our findings from modelling of expression, differential expression analysis and transcription factor binding site (TFBS) enrichment with key clinical features of SSc. We detected 49,123 validated cis-eQTLs from 4,539 SSc associated SNPs (p <10 ) and 565 of 1.436 genes with an SSc eQTL within 1 Mb distance to the gene. We developed a strategy to prioritize disease-associated genes based on their expression variance explained by SSc eQTLs (r >0.05). As a result, 233 candidates were identified, 134 (58%) of them associated with hallmarks of SSc and 105 (45%) of them differentially expressed in blood cells, skin, or lung tissue of SSc patients. TFBS analysis revealed enriched motifs of 24 TFs (5%) among SSc eQTLs, five of which were found to be differentially regulated in blood cells (ELF1 and MGA), skin (KLF4 and ID4), and lungs (TBX4) of SSc patients. Ten candidate genes (4%) can be targeted by approved medications for immune-mediated diseases, of which only two have been tested in clinical trials in patients with SSc. The data of the present study provides a new layer of the molecular complexity of SSc, contributing to a better understanding of the pathogenesis of the disease.
ISSN:2326-5205